资讯
内科
心血管
肿瘤
内分泌
普通内科
消化
呼吸
神经科
传染科
精神心理
肾内科
风湿免疫
血液科
老年医学
外科
头颈外科
胃肠外科
血管外科
肝胆胰外
骨科
普通外科
胸心外科
神经外科
泌尿外科
烧伤科
整形美容
麻醉疼痛
专科科室
罕见病
康复医学
药械
儿科
耳鼻咽喉
口腔科
眼科
政策人文
营养全科
预防公卫
妇产科
中医科
急重症
皮肤性病
影像放射
转化医学
检验病理
护理
热点
临床研究
研究设计
人工智能
智慧医疗
论文基金
医学科普
药物经济
医生集团
职业安全
患者招募
医学科研
公司产业
医学英语
MedSci动态
指南
按科室浏览
肿瘤科
心血管
传染科
妇产科
神经科
儿科
呼吸
内分泌科
血液科
消化
更多科室
工具
临床工具
临床指南
医学计算与公式
ICD-10/ICD-11疾病编码
医讯达
直播
话题
公开课
精品课
科研工具
期刊数据库查询
期刊智能选择
全球基金查询
文献查询
SCI写作宝典
生物医药大词典
其他工具
下载App使用方便更快捷
Medsci 梅斯搜索
公开课
精品课
服务
科研数智化
直播,公开课与精品课
科研加速器
研究者发起的临床研究(IIS)支持
真实世界研究解决方案
药物经济学
医保准入事务
研究方案设计
数据库建立与管理
药物警戒(PV)
真实世界研究执行
数据统计分析
数字化学术传播解决方案
多渠道营销(MCM)
产品医学策略
学术传播(APO)
其它
积分商城
FAQS
#AACR#
120篇内容 | 3112人围观
关注话题
话题活跃用户
#
插入话题
插入图片
评论
最新
最热
GetTopicDetailResponse(id=169c166430, topicName=AACR, introduction=AACR, content=null, image=null, comments=120, allHits=3112, url=https://h5.medsci.cn/topic?id=1664, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=2963, tagList=[TagDto(tagId=2963, tagName=AACR)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1552021, encodeId=9e6215520217b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存(IMspire150试验), objectType=article, longId=193346, objectId=688d193346bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=688d193346bb, replyNumber=0, likeNumber=101, createdTime=2020-05-03, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=688d193346bb, moduleTitle=AACR 2020:靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存(IMspire150试验), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=688d193346bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552020, encodeId=8b9d1552020e5, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS(FLAURA研究), objectType=article, longId=193345, objectId=a58619334571, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a58619334571, replyNumber=0, likeNumber=55, createdTime=2020-05-03, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a58619334571, moduleTitle=AACR 2020:基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS(FLAURA研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a58619334571)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552019, encodeId=b3bf1552019d0, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, objectType=article, longId=193342, objectId=4e5d193342f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e5d193342f4, replyNumber=0, likeNumber=75, createdTime=2020-05-03, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e5d193342f4, moduleTitle=AACR 2020:索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e5d193342f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552018, encodeId=7fb0155201812, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, objectType=article, longId=193184, objectId=fb6d193184c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb6d193184c5, replyNumber=0, likeNumber=112, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb6d193184c5, moduleTitle=AACR 2020:CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb6d193184c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552017, encodeId=2b5c155201e13, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:MET新药Bozitinib用于NSCLC,疾病控制率90%, objectType=article, longId=193183, objectId=1bf61931836e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1bf61931836e, replyNumber=0, likeNumber=60, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1bf61931836e, moduleTitle=AACR 2020:MET新药Bozitinib用于NSCLC,疾病控制率90%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1bf61931836e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552016, encodeId=7dd91552016c7, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:KRAS新药用于NSCLC结果公布, objectType=article, longId=193182, objectId=863c19318287, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=863c19318287, replyNumber=0, likeNumber=75, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=863c19318287, moduleTitle=AACR 2020:KRAS新药用于NSCLC结果公布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=863c19318287)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552015, encodeId=f9481552015f5, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, objectType=article, longId=193181, objectId=fa86193181f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa86193181f6, replyNumber=0, likeNumber=70, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa86193181f6, moduleTitle=AACR 2020:EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa86193181f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552014, encodeId=0508155201487, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:蔡红兵教授分享COVID-19疫情癌症患者的数据, objectType=article, longId=193180, objectId=31a5193180d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31a5193180d8, replyNumber=0, likeNumber=0, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31a5193180d8, moduleTitle=AACR 2020:蔡红兵教授分享COVID-19疫情癌症患者的数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31a5193180d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552013, encodeId=33921552013d9, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:肝内胆管癌的FGFR2一个新型突变被发现, objectType=article, longId=193179, objectId=833e1931e9c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833e1931e9c2, replyNumber=0, likeNumber=73, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833e1931e9c2, moduleTitle=AACR 2020:肝内胆管癌的FGFR2一个新型突变被发现, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833e1931e9c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552012, encodeId=50921552012fe, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌,未获成功, objectType=article, longId=193178, objectId=3bf01931e84c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3bf01931e84c, replyNumber=0, likeNumber=58, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3bf01931e84c, moduleTitle=AACR 2020:PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌,未获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3bf01931e84c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552011, encodeId=1a0f1552011af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:基因治疗肾细胞癌获突破,DCR可达75%!, objectType=article, longId=193177, objectId=1d271931e730, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1d271931e730, replyNumber=0, likeNumber=77, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1d271931e730, moduleTitle=AACR 2020:基因治疗肾细胞癌获突破,DCR可达75%!, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1d271931e730)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552010, encodeId=031f1552010ed, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:KRAS突变在不同癌肿的发生率, objectType=article, longId=193176, objectId=cdb61931e68c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdb61931e68c, replyNumber=0, likeNumber=60, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdb61931e68c, moduleTitle=AACR 2020:KRAS突变在不同癌肿的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdb61931e68c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552009, encodeId=8110155200931, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:免疫联合治疗在三阴性乳腺癌治疗中获突破,OS高达16个月, objectType=article, longId=193174, objectId=9c411931e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c411931e4ea, replyNumber=0, likeNumber=0, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c411931e4ea, moduleTitle=AACR 2020:免疫联合治疗在三阴性乳腺癌治疗中获突破,OS高达16个月, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c411931e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552008, encodeId=95e015520086b, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, objectType=article, longId=193172, objectId=24cd1931e229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24cd1931e229, replyNumber=0, likeNumber=69, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24cd1931e229, moduleTitle=AACR 2020:Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24cd1931e229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552007, encodeId=7a66155200eda, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:肿瘤浸润淋巴细胞(TIL)疗法挑战PD-1耐药性肺癌, objectType=article, longId=193170, objectId=53521931e076, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=53521931e076, replyNumber=0, likeNumber=73, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=53521931e076, moduleTitle=AACR 2020:肿瘤浸润淋巴细胞(TIL)疗法挑战PD-1耐药性肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=53521931e076)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552006, encodeId=05ef1552006af, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:伯瑞替尼治疗MET异常NSCLC,ORR达30.5%, objectType=article, longId=193168, objectId=64ac1931686b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ac1931686b, replyNumber=0, likeNumber=70, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ac1931686b, moduleTitle=AACR 2020:伯瑞替尼治疗MET异常NSCLC,ORR达30.5%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64ac1931686b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552005, encodeId=f5fd1552005f5, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), objectType=article, longId=193163, objectId=3f4219316311, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f4219316311, replyNumber=0, likeNumber=51, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f4219316311, moduleTitle=AACR 2020:厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f4219316311)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552004, encodeId=134d15520047a, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:拉罗替尼治疗TRK融合肿瘤的亚组分析, objectType=article, longId=193161, objectId=31991931618c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31991931618c, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31991931618c, moduleTitle=AACR 2020:拉罗替尼治疗TRK融合肿瘤的亚组分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31991931618c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552003, encodeId=1a9d1552003df, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:波奇替尼治疗NSCLC的EGFR 20ins的II期研究, objectType=article, longId=193160, objectId=a05f193160ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a05f193160ff, replyNumber=0, likeNumber=82, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a05f193160ff, moduleTitle=AACR 2020:波奇替尼治疗NSCLC的EGFR 20ins的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a05f193160ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1552002, encodeId=52681552002ca, content=<a href='/topic/show?id=169c166430' target=_blank style='color:#2F92EE;'>#AACR#</a>, objectTitle=AACR 2020:Capmatinib治疗MET 14突变的NSCLC脑转移疗效, objectType=article, longId=193158, objectId=b7d619315856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7d619315856, replyNumber=0, likeNumber=68, createdTime=2020-05-01, rootId=0, userName=Luyuxie_14, userId=6b2714248200, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7d619315856, moduleTitle=AACR 2020:Capmatinib治疗MET 14突变的NSCLC脑转移疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7d619315856)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯话题小助手
关注
已关注
AACR
2020-05-29
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:靶向联合免疫治疗显著延长BRAF突变晚期黑色素瘤患者无进展生存(IMspire150试验)
101
0
2020-05-03
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:基于ctDNA的复合型预测模型有效预测EGFR突变阳性晚期NSCLC一线治疗PFS(FLAURA研究)
55
0
2020-05-03
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:索凡替尼联合特瑞普利单抗治疗晚期实体瘤Ⅰ期研究结果公布
75
0
2020-05-03
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:CAR-T治疗复发性或难治性(R/R)急性T淋巴细胞白血病试验初步结果公布
112
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:MET新药Bozitinib用于NSCLC,疾病控制率90%
60
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:KRAS新药用于NSCLC结果公布
75
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:EGFR/HER2新药Mobocertinib用于NSCLC EGFR 20ins突变ORR达43%
70
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:蔡红兵教授分享COVID-19疫情癌症患者的数据
0
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:肝内胆管癌的FGFR2一个新型突变被发现
73
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:PD-L1+恩杂鲁胺治疗去势抵抗性前列腺癌,未获成功
58
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:基因治疗肾细胞癌获突破,DCR可达75%!
77
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:KRAS突变在不同癌肿的发生率
60
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:免疫联合治疗在三阴性乳腺癌治疗中获突破,OS高达16个月
0
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:Durvalumab+奥拉帕利+紫杉醇用于高危HER2阴性乳腺癌新辅助治疗创新高
69
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:肿瘤浸润淋巴细胞(TIL)疗法挑战PD-1耐药性肺癌
73
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:伯瑞替尼治疗MET异常NSCLC,ORR达30.5%
70
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:厄洛替尼±雷莫芦单抗一线治疗NSCLC EGFR突变III期研究的NGS下结果(RELAY研究)
51
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:拉罗替尼治疗TRK融合肿瘤的亚组分析
68
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:波奇替尼治疗NSCLC的EGFR 20ins的II期研究
82
0
2020-05-01
回复
Luyuxie_14
(审核中...)
关注
已关注
前往app查看评论内容
#AACR#
AACR 2020:Capmatinib治疗MET 14突变的NSCLC脑转移疗效
68
0
2020-05-01
回复
共121条
首页
上一页
下一页
尾页
页码:
3
/7页
20条/页
扫描二维码下载梅斯医学APP
科室
订阅+
更多科室
工具
服务